Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review

Psychotherapy and Psychosomatics

Volumn 84, Issue 2, 2015, Pages 72-81

  Fava, Giovanni A ^a,b   Gatti, Alessia ^a   Belaise, Carlotta ^a   Guidi, Jenny ^a   Offidani, Emanuela ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adverse events; Antidepressive agents; Anxiety; Depression; Discontinuation syndrome; Selective serotonin reuptake inhibitors; Side effects; Tolerance; Withdrawal symptoms

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CINAHL; COCHRANE LIBRARY; DRUG WITHDRAWAL; HUMAN; INVESTIGATIVE PROCEDURES; MEDLINE; OPEN STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; WITHDRAWAL SYNDROME;

EID: 84924122385     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000370338     Document Type: Review

References (96)

1. Stoukides J, Stoukides C: Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991; 148: 1263.
2. Szabadi E: Fluvoxamine withdrawal syndrome. Br J Psychiatry 1992; 160: 283-284.
3. Black D, Wesner R, Gabel J: The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 54: 146-149.
4. Barr L, Goodman W, Price L: Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 1994; 151: 289.
5. Einbinder E: Fluoxetine withdrawal? Am J Psychiatry 1995; 152: 1253.
6. Debattista C, Schatzberg A: Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry 1995; 152: 1235-1236.
7. Dominguez R, Goodnick P: Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995; 15: 778-780.
8. Bloch M, Stager S, Braun A, Rubinow D: Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet 1995; 346: 57.
9. Frost L, Lal S: Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry 1995; 152: 810.
10. Kasantikul D: Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thai 1995; 78: 53-54.
11. Phillips S: A possible paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152: 645-646.
12. Pyke R: Paroxetine withdrawal syndrome. Am J Psychiatry 1995; 152: 149-150.
13. Fava G, Grandi S: Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol 1995; 15: 374-375.
14. Leiter F, Nierenberg A, Sanders K, Stern T: Discontinuation reaction following sertraline. Biol Psychiatry 1995; 38: 694-695.
15. Pacheco L, Malo P, Aragues E: More cases of paroxetine withdrawal syndrome. Br J Psychiatry 1996; 169: 384.
16. Rosenstock H: Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmacol 1996; 11: 58-59.
17. Zajecka J, Fawcett J, Amsterdam J: Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18: 193-197.
18. Lejoyeux M, Adès J: Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997; 58: 11-16.
19. Medawar C: The antidepressant web. Int J Risk Safety Med 1997; 10: 75-126.
20. Therrier F, Markowitz J: Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature. Hum Psychopharmacol 1997; 12: 309-323.
21. Olver JS, Burrows GD, Norman TR: Discontinuation syndromes with selective serotonin reuptake inhibitors. CNS Drugs 1999; 12: 171-177.
22. Rosenbaum J, Fava M, Hoog S, Ascroft R, Krebs W: Selective serotonin reuptake inhibitors discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77-87.
23. Black K, Shea C, Dursun S, Kutcher S: Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatr Neurosci 2000; 25: 255-261.
24. Shelton R: The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 2006; 67: 3-7.
25. Warner C, Bobo W, Warner C, Reid S, Rachal J: Antidepressant discontinuation syndrome. Am Fam Physician 2006; 74: 449-456.
26. Schatzberg AF, Blier P, Delgado P, Fava M, Haddad PM, Shelton RC: Antidepressant discontinuation syndrome. J Clin Psychiatry 2006; 67: 27-30.
27. Nielsen M, Hansen E, Gotzsche P: What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012; 107: 900-908.
28. Renoir T: Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. Front Pharmacol 2013; 4: 1-10.
29. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
30. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386-388.
31. Chouinard G: Issues in the clinical use of benzodiazepines: potency, withdrawal and rebound. J Clin Psychiatry 2004; 1(suppl 5): 7-12.
32. Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, Calberg H, Judge R, Ohrstrom JK, Manniche PM: Paroxetine in the treatment of panic disorder: a randomized, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374-379.
33. Markowitz J, DaVane C, Liston H, Montgomery S: An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15: 329-333.
34. Robert P, Montgomery SA: Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6-month study. Int Clin Psychopharmacol 1995; 10: 29-35.
35. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; 334: 1-100.
36. Montgomery S, Nil R, Durr-Pal N, Loft H, Boulenger J: A 24-week randomized, doubleblind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270-1278.
37. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, Tepner R: Interruption of selective serotonin reuptake inhibitor treatment. Double-blind placebo-controlled trial. Br J Psychiatry 2000; 176: 363-368.
38. Judge R, Parry M, Quail D, Jacobson J: Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17: 217-225.
39. Montgomery S, Kennedy S, Lejoyeux M, Hindmarch I: Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebocontrolled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271-280.
40. Hindmarch I, Kimber S, Cocle S: Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15: 305-318.
41. Montgomery S, Huusom A, Bothmer J: A randomised study comparing escitalopram with venlafaxine XR patients in primary care with major depressive disorder. Neuropsychobiology 2004; 50: 57-64.
42. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, Martin AJ, Lam W, Burt T: Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66: 1312-1320.
43. Lader M, Stender K, Burger V, Nil R: Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: a randomized, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241-248.
44. Baldwin D, Huusom A, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264-272.
45. Baldwin D, Cooper J, Huusom A, Hindmarch I: A double-blind, randomized, parallelgroup, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006; 21: 159-169.
46. Tint A, Haddad P, Anderson I: The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomized study. J Psychopharmacol 2008; 22: 330-332.
47. Haddad P, Lejoyeux M, Young A: Antidepressant discontinuation reactions are preventable and simple to treat. BMJ 1998; 316: 1105-1106.
48. Mallya G, White K, Gunderson C: Is there a serotoninergic withdrawal syndrome? Biol Psychiatry 1993; 33: 851-852.
49. Bogetto F, Bellino S, Bonatto R, Patria L: Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16: 273-283.
50. Fava G, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835-838.
51. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
52. Coupland NJ, Bell C, Potokar JP: Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356-362.
53. Price J, Waller P, Wood S, Mackay A: A comparison of the post-marketing safety of four selective serotonin reuptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757-763.
54. Himei A, Okamura T: Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factor involved in the occurrence of the syndrome. CNS Drugs 2006; 20: 665-672.
55. Van Geffen E, Hugtenburg J, Heerdink E, Van Hulten R, Egberts A: Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Psychopharmacol 2005; 61: 303-307.
56. Cooper G: The safety of fluoxetine: an update. Br J Psychiatry 1988; 153: 77-86.
57. Poryazova R, Siccoli M, Werth E, Bassetti C: Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005; 65: 967-968.
58. Blum D, Maldonado J, Meyer E, Lanberg M: Delirium following abrupt discontinuation of fluoxetine. Clin Neurol Neurosurg 2008; 110: 69-70.
59. Bhanji N, Chouinard G, Kolivakis T, Margolese H: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound withdrawal phenomena. Can J Clin Pharmacol 2006; 13: 69-74.
60. Keuthen N, Cyr P, Ricciardi J: Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. Int Clin Psychopharmacol 1994; 14: 206-207.
61. Milliken C, Cooper S: Withdrawal symptoms from paroxetine. Hum Psychopharmacol 1998; 13: 217-219.
62. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent post-withdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014; 83: 247-248.
63. Yasui-Furukori N, Kaneko S: Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 2011; 65: 384-385.
64. Polimeni G, Grugno R, Cordici F, Vietta A, Caputi A, Bramanti P: Nocturnal enuresis after paroxetine abrupt discontinuation: a case report. J Clin Psychopharmacol 2008; 28: 589-591.
65. Mazzatenta C, Peonia G, Martini P: Pruritus induced by interruption of paroxetine therapy. Br J Dermatol 2004; 150: 787.
66. Landry P, Roy L: Withdrawal hypomania associated with paroxetine. J Clin Psychopharmacol 1997; 17: 60-61.
67. Shoenberger D: Discontinuing paroxetine: a personal account. Psychother Psychosom 2002; 71: 237-238.
68. Louie A, Lannon R, Ajari L: Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 1994; 151: 450.
69. Levenson J: Putative neuroleptic malignant syndrome associated with sertraline withdrawal. J Clin Psychopharmacol 2009; 29: 300-301.
70. Benazzi F: Psychotic mania in bipolar II depression related to sertraline discontinuation. Can J Psychiatry 2002; 47: 584-585.
71. Amsden G, Georgian F: Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 1996; 16: 684-686.
72. Benazzi F: SSRI discontinuation syndrome related to fluvoxamine. Rev Psychiatr Neurosci 1998; 23: 94.
73. Hirose S: Restlessness related to SSRI withdrawal. Psychiatry Clin Neurosci 2001; 55: 77-80.
74. Benazzi F: Citalopram withdrawal symptoms. Eur Psychiatry 1998; 13: 219.
75. Fernando A, Schwader P: A case of citalopram withdrawal. J Clin Psychopharmacol 2000; 20: 581-582.
76. Adson D, Kotlyar M: Premature ejaculation associated with citalopram withdrawal. Ann Pharmacother 2003; 37: 1804-1806.
77. Feth N, Cattapan-Ludewig K, Jaquenoud-Sirot E: Electric sensations: neglected symptom of escitalopram discontinuation. Am J Psychiatry 2006; 163: 160.
78. Prakash O, Dhar V: Emergence of electric shock-like sensations on escitalopram discontinuation. J Clin Psychopharmacol 2008; 28: 359-360.
79. Tomba E, Offidani E, Fava GA: Selective serotonin reuptake inhibitors withdrawal syndromes: new insights into pathophysiology and treatment; in Rees JP, Woodhouse OB (eds): Substance Withdrawal Syndrome. New York, Nova Science, 2009, pp 37-60.
80. Bitter I, Filipovits D, Czobor P: Adverse reactions to duloxetine in depression. Expert Opin Drug Saf 2011; 10: 839-850.
81. Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237-256.
82. Blier P, Tremblay P: Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 2006; 67: 8-13.
83. Harvey BH, McEwen BS, Stein DJ: Neurobiology of antidepressant withdrawal: implications for longitudinal outcome of depression. Biol Psychiatry 2003; 54: 1105-1117.
84. Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R, Koyama S, Mine K: Effects of serotonin 1A, 2A, 2C, 3A and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol 2010; 30: 11-17.
85. Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593-1602.
86. Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014; 83: 197-204.
87. Offidani E, Guidi J, Tomba E, Fava GA: Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom 2013; 82: 355-362.
88. Fava GA, Tomba E: The use of antidepressant drugs: some reasons for concern. Int J Risk Safety Med 1998; 11: 271-274.
89. Fava GA, Tomba E, Tossani E: Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40: 306-311.
90. Offidani E, Fava GA, Sonino N: Iatrogenic comorbidity in childhood and adolescence: new insights from the use of antidepressant drugs. CNS Drugs 2014; 28: 769-774.
91. Carvalho AF, Berk M, Hyphantis TN, McIntyre RS: The integrative management of treatment resistant depression. Psychother Psychosom 2014; 83: 70-88.
92. Bergh S, Selbaek G, Engedal K: Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP Study). BMJ 2012; 344: 1566.
93. Cerovecki A, Musil R, Klimke A, Seemuller F, Haen E, Schennach R, Kuhn KU, Volz HP, Riedel M: Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics. CNS Drugs 2013; 27: 545-572.
94. Rickels K: Should benozodiazepines be replaced by antidepressants in the treatment of anxiety disorders? Fact or fiction? Psychother Psychosom 2013; 82: 351-352.
95. Balon R: Benzodiazepines revisited. Psychother Psychosom 2013; 82: 353-354.
96. Kosten TR, O'Connor PG: Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-1795.